BioVectra

Overview

BioVectra is a Canadian contract development and manufacturing organization (CDMO) with 50+ years of experience serving 100+ active clients across five geographic markets, including 18 of the top 20 pharma and biotech companies. The organization specializes in clinical-to-commercial scale production across multiple modalities and therapeutic areas.

Core Capabilities

Biologics Manufacturing

• Recombinant protein development and manufacturing in microbial systems
• Plasmid DNA and mRNA production
• Antibody fragment manufacturing
• Microbial fermentation from pilot to commercial scale

Small Molecules & APIs

• Synthetic small molecule process development and manufacturing
• Fermented small molecule production
• Highly potent API (HPAPI) process development and commercial production
• Extensive experience in complex microbial fermentation

Bioreagents

• High-quality bioreagents in multiple package sizes
• GMP-grade materials for research through manufacturing scale operations

Facilities & Infrastructure

BioVectra operates multiple cGMP facilities across Prince Edward Island and Nova Scotia:

• Research & Development facility (17 Hillstrom Ave., PE): lab and pilot scale
• Headquarters (11 Aviation Ave., PE): pilot, GMP, and large-scale commercial capabilities
• New API Facility (11 Aviation Ave., PE): lab GMP and large-scale commercial GMP
• Large Scale Biomanufacturing Facility (24 Ivey Lane, NS): lab, pilot, clinical, and large-scale commercial
• Dedicated Natural Extraction Facility (29 McCarville St., PE)

Differentiation

The organization emphasizes flexibility, creativity, and dedication to process optimization. Leadership highlights the ability to address complex manufacturing challenges that few CDMOs possess the expertise to tackle, with a proven track record of 10+ partnered capacity expansion projects since 2003.